The signing ceremony of the strategic cooperation between Beijing Scitech-MQ Pharmaceuticals Limited（hereinafter referred to as “SciTech Pharma”）and Shanghai Oriental Hospital was successfully held in Shanghai on December 18. Li Qinchuan, secretary of the Party Committee of Shanghai Oriental Hospital, Li Jin, Director of Department of Medical Oncology, Guo Ye, Director of Phase I Clinical Trial Center, Wang Kexiu, Chairman of SciTech Pharma, Zhang Qiang, President and Chief Scientific Officer of SciTech Pharma, Qin Shukui, Phase I Clinical Chief Advisor of Shanghai Oriental Hospital, Ma Jing, Chief Advisor of Biomedical Industry of Shanghai Lingang Group, as well as representatives of clinical trial institution and physicians of Shanghai Oriental Hospital, representatives of SMO START, and representatives of SciTech Pharma and some pharmaceutical colleagues attended the signing ceremony.
Wang Kexiu, Chairman and Zhang Qiang, President and Chief Scientific Officer of SciTech Pharma and Li Qinchuan, secretary of the Party Committee and Li Jin, Director of Department of Medical Oncology of Shanghai Oriental Hospital signed the strategic cooperation agreement.
According to the strategic cooperation agreement, SciTech Pharma and Shanghai Oriental Hospital will integrate their respective advantageous resources to carry out in-depth cooperation in the clinical research of several innovative anti-tumor drugs and establish a comprehensive strategic partnership to achieve resource exchange and complementary advantages, with a view to improving the efficiency of drug development, addressing unmet clinical needs and contributing to the development of life sciences in China.
The signing of this strategic cooperation marks the mutual trust and recognition between SciTech Pharma and Shanghai Oriental Hospital. Both parties plan to further expand their cooperation in the future and conduct phase I clinical research collaboration in several solid tumor areas including liver cancer, pancreatic cancer, breast cancer, colon cancer, etc., to rapidly advance more new tumor drugs to clinical research in order to accelerate the development of innovative drugs and benefit patients in China and worldwide as soon as possible.
